文献速递食管与纵隔外科

食管切除术后吻合口复发的治疗

Treatment of Anastomotic Recurrence After Esophagectomy.
PubMed 文献 · Ann Thorac Surg · 2021-09-10

该回顾性队列纳入2000至2019年1370例食管腺癌(EAC)切除术患者,其中531例(39%)复发。局部复发5年累积发生率2.7%(95%CI 2.0%-3.6%)。局部复发患者接受根治性治疗的中位复发后生存为19.1个月(95%CI 11.4-33.2个月),优于单纯化放疗的10.6个月(95%CI 8.5-14.2个月)和未治疗的1.73个月(95%CI 0.23-15.6个月)(P < .001)。

要点

  • 局部复发5年累积发生率为2.7%,远处复发为22.0%。
  • 进展期pT分期、印戒细胞组织学及严重并发症是局部复发的独立危险因素。
  • 根治性治疗组复发后中位生存19.1个月,优于单纯化放疗和未治疗组。

核心结论

  • 孤立性局部复发仅见于约3%的患者。
  • 进展期T分期、印戒细胞组织学及严重并发症是复发的危险因素。
  • 尽管需要复杂的手术切除,在经高度选择的病例中,更积极的治疗可能是合理的。

研究设计与样本

  • 回顾性队列研究,纳入2000至2019年接受食管切除术的食管腺癌(EAC)患者1370例。
  • 采用Kaplan-Meier法估计复发后总生存,log-rank检验比较治疗组间差异。
  • 采用单变量和多变量竞争风险回归分析危险因素。

主要发现

  • 531例(39%)患者出现疾病复发。
  • 局部复发5年累积发生率为2.7%(95%CI 2.0%-3.6%),区域复发为6.3%(95%CI 5.2%-7.8%),远处复发为22.0%(95%CI 20.0%-24.4%)。
  • 局部复发患者接受根治性治疗的中位复发后生存为19.1个月(95%CI 11.4-33.2个月),单纯化疗或放疗为10.6个月(95%CI 8.5-14.2个月),未治疗为1.73个月(95%CI 0.23-15.6个月)(P < .001)。

临床怎么用

  • 对食管腺癌术后患者,应关注进展期pT分期、印戒细胞组织学及严重并发症等局部复发危险因素。
  • 对于经高度选择的孤立性局部复发患者,可考虑根治性治疗以改善生存。

局限性

  • 本研究为单中心回顾性研究,可能存在选择偏倚。
  • 根治性治疗组样本量可能较小,需谨慎解读生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isolated local recurrence after curative esophagectomy for esophageal cancer is a rare event. Although it is potentially curable, management can be challenging. METHODS: We retrospectively reviewed all patients undergoing esophagectomy for esophageal adenocarcinoma (EAC) from 2000 to 2019. Date of recurrence was defined as the date at which the initial abnormal surveillance study result or symptomatic presentation led to further workup and subsequent pathologic diagnosis of recurrence. Overall survival after recurrence was estimated using Kaplan-Meier methods and compared between treatment groups using the log-rank test. RESULTS: Of the 1370 patients with EAC who underwent esophagectomy in our cohort, 531 (39%) developed recurrence of their disease. The 5-year cumulative incidence of recurrence was 2.7% (95% CI, 2.0%-3.6%) for local, 6.3% (95% CI, 5.2%-7.8%) for regional, and 22.0% (95% CI, 20.0%-24.4%) for distant recurrences. On univariable and multivariable competing-risk regression analysis, advanced pT stage, signet ring histology, and serious complication were independently associated with local recurrence. Patients with local recurrence treated with definitive therapy had a median survival after recurrence of 19.1 months (95% CI, 11.4-33.2 months) compared with 10.6 months (95% CI, 8.5-14.2 months) for chemotherapy or radiotherapy alone and 1.73 months (95% CI, 0.23-15.6 months) for no treatment (P < .001). CONCLUSIONS: Isolated local recurrence occurred in only 3% of patients. Advanced T stage, signet cell histology, and serious complication were risk factors for recurrence. Although complex surgical resection is required, in very select cases, more aggressive treatment may be warranted.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Carr RA, Harrington C, Vos E, et al. Treatment of Anastomotic Recurrence After Esophagectomy. Ann Thorac Surg. 2021. PMID: 34509415. doi:10.1016/j.athoracsur.2021.07.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。